In the following video, Fool contributor Maxx Chatsko discusses the recent investment by Johnson & Johnson (NYSE:JNJ) into a tiny start-up called Second Genome. Although terms of the deal were not disclosed, it is not believed to have been very significant. In monetary terms, anyway. Second Genome is actively pursuing links between the bacteria living in your gut -- the microbiome -- and autoimmune diseases such as ulcerative colitis. There is growing evidence suggesting the microbiome plays a big role in our overall health, so Big Pharma would be well served to follow Johnson & Johnson's lead.
Jun 14, 2013 at 6:37PM
Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 05/07/2021.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return